A Münster-based medtech company has pulled in fresh capital to bring its operating-room imaging system to market—if it can clear the regulatory hurdles first.
When surgeons operate on cancer patients, they face an uncomfortable trade-off: cut too conservatively and risk leaving malignant tissue behind, or go too wide and damage healthy organs. The wait for pathology results can stretch for days, sometimes forcing patients back under the knife for a second procedure when the margins weren't quite right the first time.
Refined Diagnostics thinks it has a way out of that dilemma. The Münster-based startup announced on July 7, 2026, that it had closed €2.9 million in growth capital—money earmarked for pushing its real-time tissue analysis system toward clinical use. Companisto Business Angel Network led the round, with backing from both existing and new co-investors. The company also landed €2.6 million in non-dilutive public funding from EU and North Rhine-Westphalia sources, nudging its total haul past €10 million since spinning out of the University of Münster in 2019.
It's a meaningful milestone for a company still working to prove its technology belongs in the operating room.
The Promise of Virtual Histology
At the core of Refined's pitch is Aquila, an intraoperative imaging system that relies on Raman spectroscopy—a technique that bounces laser light off tissue samples to create a molecular fingerprint. The company calls the result "virtual histology," claiming it can deliver pathology-grade insights in minutes rather than the days required for traditional analysis.
In theory, that could change surgical decision-making on the fly. No more sending samples to a lab, waiting through anxious post-op hours, and scheduling follow-up procedures when initial resections miss their mark.
But theory and practice don't always align neatly in medtech, particularly when regulators are involved. Refined's product documentation is forthright about where things stand: Aquila is "not for clinical use, not CE marked under EU IVDR and not FDA cleared." The system remains, in regulatory parlance, very much under development.
Still, the company says it has wrapped up its first clinical study and is running four more. CE certification, according to Refined, is "well underway," with the team "very close to IVD-A approval." (That's the in-vitro diagnostic classification under European Union rules.)
An April 2026 study published in Cancers, a peer-reviewed journal, offered a glimpse of what that clinical work looks like. Researchers, including Refined's personnel, described a multicenter trial testing Refined's fiber-based picosecond laser technology during glioblastoma surgeries—a particularly aggressive form of brain cancer. The authors suggested the approach could serve as a useful complement to frozen-section analysis, though they noted the need for further studies to nail down accuracy across different tumor grades and tissue types.
Translation: promising, but not definitive. Which is roughly where most early-stage medical devices sit before they cross the approval threshold.
Targeting a 2027 Launch
The fresh capital is meant to fund that final sprint. Refined says it's targeting a 2027 clinical market entry—a timeline that assumes regulatory approvals land as expected and that hospitals are ready to adopt the technology once it clears.
The company has been laying groundwork on both fronts. It claims engagement with more than 40 hospitals and participation in two German government-backed clinical research programs: KURE, based at University Hospital Dresden, and KIROP at RWTH Aachen. Both focus on intraoperative diagnostics for brain and abdominal cancers, which gives Refined access to real-world surgical settings and the data needed to satisfy regulators.
The team—led by co-founders Dr. Max Brinkmann, Dr. Tim Hellwig, and Christoph Seidenstücker—has been at this for a while now. Back in late January 2023, the company raised €2.7 million in seed funding from High-Tech Gründerfonds and APEX Ventures, with participation from NRW.BANK, Onsight Ventures, and Papst Venture Capital. (High-Tech Gründerfonds, for context, is a German public-private fund that backs early-stage tech companies; APEX focuses on deep-tech ventures.)
Refined noted in its July announcement that it's in advanced discussions with additional venture investors for what it describes as a "final closing" of the current round. Whether that materializes—and how much more capital the company can pull in—may depend on how quickly it can move from clinical trials to commercial sales.
For now, the company is still navigating that uncertain middle ground where the technology shows enough promise to attract investors but hasn't yet convinced regulators or clinicians that it's ready for routine use. It's a familiar position for medical device startups, and one that tends to separate the companies that eventually break through from those that don't.
The next year or so will likely tell us which category Refined Diagnostics falls into.
